Suppressive antiretroviral therapy (ART) substantially decreases HIV transmission in clinical research settings. We sought to measure the frequency and correlates of periods of transmission risk among individuals taking ART during multiple years of observation in rural, southwestern Uganda.
Observational cohort study.
We collected sexual behavior and viral load data in a Ugandan cohort of people living with HIV/AIDS from the time of ART initiation. We defined each 90-day visit as a potential transmission period if HIV-1 RNA was more than 400 copies/ml and the participant reported sexual transmission risk behavior, defined as unprotected sexual contact with at least 1 HIV-uninfected partners or partners of unknown serostatus in the prior 90 days.
We evaluated data from 463 individuals on ART over a median 3.5 years of observation and 5293 total study visits. During that time, over half (259, 56%) had detectable viremia or reported sexual transmission risk behavior at least once. However, only 23 (5%) had both simultaneously, at 28 (<1%) of all visits. Transmission sexual behavior was reported at 6% of visits with detectable viremia. In multivariable regression modeling, correlates of transmission risk periods included younger age, lower CD4+ cell count, low household asset ownership and increased internalized stigma.
Although detectable viremia and/or sexual transmission risk behavior occurred in over half of individuals, ART reduced periods of HIV transmission risk by over 90% during up to 6 years of observation time. These findings provide further support for provision of ART, along with interventions to promote long-term adherence, to reduce HIV transmission in HIV-endemic settings.
Supplemental Digital Content is available in the text
aMassachusetts General Hospital, Center for Global Health, Boston, Massachusetts, USA
bMbarara University of Science and Technology, Mbarara, Uganda
cChester M. Pierce MD Division of Global Psychiatry, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA
dUniversity of California, San Francisco, California, USA
eRagon Institute of Massachusetts General Hospital MIT and Harvard, and Harvard Medical School, Boston, Massachusetts, USA.
Correspondence to Mark Siedner, Massachusetts General Hospital, Division of Infectious Diseases, 55 Fruit St., GRJ-5, Boston, MA 02114, USA. Tel: +1 617 732 6829; e-mail: firstname.lastname@example.org
Received 2 August, 2013
Revised 1 November, 2013
Accepted 1 November, 2013
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).